Varela Cives R, Bautista Casasnovas A, Alonso Martin A, Pombo Arias M, Tojo Sierra R
Complejo Hospitalario Universitario, de Santiago, Spain.
Eur J Pediatr. 1996 Nov;155(11):932-6. doi: 10.1007/BF02282881.
To investigate the effects of patency of the vaginal process (processus vaginalis testis) on the efficacy of hormonal treatment of cryptorchidism, we carried out a blind, controlled, prospective study in which all patients underwent inguinal herniography. The sample comprised 310 boys with true cryptorchidism (244 unilateral, 66 bilateral) and without symptomatic hernia/ hydrocele or other pathologies. Patients age ranged from 8 months to 11 years 5 months. All patients were treated with human chorionic gonadotropin (twice-weekly intramuscular injections for 5 weeks; total dose 2500 IU for patients less than 1-year-old, 5000 IU for 1- to 6-year-olds, 10000 IU for 6- to 11-year-olds). Following treatment, 37% (139/376) of the testes descended. The incidence of descent was highest for testes initially in caudal positions. Considering only non patent (i.e., normal) vaginal processes, the incidence of testis descent was 49.5% (139/281); none of the 95 testes associated with a patent vaginal process descended in response to hormone treatment.
Prior detection of patent vaginal process by inguinal herniography permits identification of a significant subset of patients for whom hormone treatment will be ineffective. Our data suggest that this predictive procedure is 100% reliable.
为研究睾丸鞘突(鞘状突)通畅与否对隐睾症激素治疗效果的影响,我们开展了一项盲法、对照、前瞻性研究,所有患者均接受腹股沟疝造影检查。样本包括310例真性隐睾症男孩(244例单侧,66例双侧),且无有症状的疝/鞘膜积液或其他病变。患者年龄范围为8个月至11岁5个月。所有患者均接受人绒毛膜促性腺激素治疗(每周两次肌肉注射,共5周;1岁以下患者总剂量2500 IU,1至6岁患者5000 IU,6至11岁患者10000 IU)。治疗后,37%(139/37)的睾丸下降。最初位于尾侧位置的睾丸下降发生率最高。仅考虑无通畅(即正常)鞘状突的情况,睾丸下降发生率为49.5%(139/281);与通畅鞘状突相关的95个睾丸中,无一个因激素治疗而下降。
通过腹股沟疝造影术预先检测到通畅的鞘状突,可识别出激素治疗无效的相当一部分患者。我们的数据表明,这种预测方法100%可靠。